Altered leucocyte trafficking and suppressed tumour necrosis factor α release from peripheral blood monocytes after intra-articular glucocorticoid treatment

被引:33
作者
Steer, JH
Ma, DTS
Dusci, L
Garas, G
Pedersen, KE
Joyce, DA [1 ]
机构
[1] Univ Western Australia, Dept Pharmacol, Nedlands, WA 6907, Australia
[2] Sir Charles Gairdner Hosp, Dept Rheumatol, Nedlands, WA 6009, Australia
[3] Western Australian Ctr Pathol & Med Res, Dept Clin Pharmacol & Toxicol, Nedlands, WA, Australia
关键词
D O I
10.1136/ard.57.12.732
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives-A generalised transient improvement may follow intra-articular administration of glucocorticoids to patients with inflammatory arthropathy. This may represent a systemic anti-inflammatory effect of glucocorticoid released from the joint, mediated through processes such as altered leucocyte trafficking or suppressed release of pro-inflammatory cytokines. Patients, who had received intraarticular injections of glucocorticoids were therefore studied for evidence of these two systemic effects. Methods-Patients with rheumatoid arthritis were studied. Peripheral blood leucocyte counts, tumour necrosis factor a (TNF alpha) release by peripheral blood monocytes, blood cortisol concentrations, and blood methylprednisolone concentration were measured for 96 hours after intraarticular injection of methylprednisolone acetate. Results-Measurable concentrations of methylprednisolone were present in blood for up to 96 hours after injection. Significant suppression of the hypothalamic-pituitary-adrenal axis persisted throughout this time. Altered monocyte and lymphocyte trafficking, as evidenced by peripheral blood monocytopenia and lymphopenia, was apparent by four hours after injection and resolved in concordance with the elimination of methylprednisolone. Granulocytosis was observed at 24 and 48 hours. Release of TNF alpha by endotoxin stimulated peripheral blood monocytes was suppressed at four hours and thereafter. Suppression was maximal at eight hours and was largely reversed by the glucocorticoid antagonist, mifepristone. Conclusions-After intra-articular injection of methylprednisolone, blood concentrations of glucocorticoid are sufficient to suppress monocyte TNF alpha release for at least four days and to transiently alter leucocyte trafficking. These effects help to explain the transient systemic response to intra-articular glucocorticoids. Suppression of TNF alpha is principally a direct glucocorticoid effect, rather than a consequence of other methylprednisolone induced changes to blood composition.
引用
收藏
页码:732 / 737
页数:6
相关论文
共 40 条
[1]  
AMANO Y, 1993, MOL PHARMACOL, V43, P176
[2]   INHIBITION OF THE PRODUCTION AND EFFECTS OF INTERLEUKIN-1 AND TUMOR-NECROSIS-FACTOR-ALPHA IN RHEUMATOID-ARTHRITIS [J].
AREND, WP ;
DAYER, JM .
ARTHRITIS AND RHEUMATISM, 1995, 38 (02) :151-160
[3]   SERUM METHYLPREDNISOLONE LEVELS FOLLOWING INTRA-ARTICULAR INJECTION OF METHYLPREDNISOLONE ACETATE [J].
ARMSTRONG, RD ;
ENGLISH, J ;
GIBSON, T ;
CHAKRABORTY, J ;
MARKS, V .
ANNALS OF THE RHEUMATIC DISEASES, 1981, 40 (06) :571-574
[4]  
ARNETT FC, 1987, ARTHRITIS RHEUM, V31, P315
[5]  
BEELEN RHJ, 1989, HUMAN MONOCYTES, P7
[6]  
BENDRUPS A, 1993, RHEUMATOL INT, V12, P217
[7]   GLUCOCORTICOID THERAPY FOR IMMUNE-MEDIATED DISEASES - BASIC AND CLINICAL CORRELATES [J].
BOUMPAS, DT ;
CHROUSOS, GP ;
WILDER, RL ;
CUPPS, TR ;
BALOW, JE .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (12) :1198-1208
[8]  
Brostjan C, 1997, J IMMUNOL, V158, P3836
[9]   A MECHANISM FOR THE ANTIINFLAMMATORY EFFECTS OF CORTICOSTEROIDS - THE GLUCOCORTICOID RECEPTOR REGULATES LEUKOCYTE ADHESION TO ENDOTHELIAL-CELLS AND EXPRESSION OF ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE-1 AND INTERCELLULAR-ADHESION MOLECULE-1 [J].
CRONSTEIN, BN ;
KIMMEL, SC ;
LEVIN, RI ;
MARTINIUK, F ;
WEISSMANN, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (21) :9991-9995
[10]   RECEPTOR-BASED PHARMACOKINETIC PHARMACODYNAMIC ANALYSIS OF CORTICOSTEROIDS [J].
DERENDORF, H ;
HOCHHAUS, G ;
MOLLMANN, H ;
BARTH, J ;
KRIEG, M ;
TUNN, S ;
MOLLMANN, C .
JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 33 (02) :115-123